Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

ContraVir to Present at the Sidoti & Company Fall 2016 Emerging Growth Convention

ContraVir Pharmaceuticals,Inc.
Posted on: 24 Oct 16

PR Newswire

EDISON, N.J., Oct. 24, 2016

EDISON, N.J., Oct. 24, 2016 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced that it will present at Sidoti & Company Fall 2016 Emerging Growth Convention, to be held November 1, 2016, in New York City.

Senior Vice President of Drug Development, Theresa Matkovits, Ph.D., will provide an overview of the company's business during a live presentation, and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. Investors interested in attending and scheduling a one-on-one meeting should click here:

Conference Details


Sidoti & Company Fall 2016 Emerging Growth Convention


Tuesday, November 1, 2016


11 a.m. (Eastern Time)


New York Marriott Marquis; New York

About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The Company is developing two novel anti-HBV compounds with complementary mechanisms of action: CMX157, a highly potent analog of the successful antiviral drug tenofovir currently in a Phase 2a clinical trial in HBV patients; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. ContraVir is also developing FV-100, an orally available nucleoside analogue prodrug for the treatment of herpes zoster, or shingles, in a Phase 3 clinical trial. In addition to direct antiviral activity, FV-100 previously demonstrated the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN) in a Phase 2 clinical study. For more information visit

For further information, please contact:

Sharen Pyatetskaya
Director of Investor Relations; (732) 902-4028

Tiberend Strategic Advisors, Inc. 
Joshua Drumm, Ph.D. (investors); (212) 375-2664

Claire LaCagnina (media); (212) 375-2686


To view the original version on PR Newswire, visit:

SOURCE ContraVir Pharmaceuticals, Inc.

PR Newswire

Last updated on: 24/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.